×

Platform to Patient

WuXi’s Laboratory Testing Division is a comprehensive integrated testing platform supporting customers across the full spectrum of their development efforts to deliver innovative medicines to patients.

At a Glance

7

R&D Sites in the US and China

2,500+

Employees Globally

450+

Global IND Packages Completed

100+

Global NDA Packages Completed

30

Clinical Centers in China

10+

Years GMP and GLP Lab Experience

430+

Validated Methods for Bioanalysis

Integrated Testing Platforms

Preclinical Drug Development (WIND)


WuXi IND (WIND) combines technical experience, program management and regulatory expertise to facilitate submission of your IND package.

Clinical Drug Development


The Laboratory Testing Division can carry your compound from early discovery all the way through clinical trials, providing consistent, streamlined support across the lifecycle of your project.

Medical Device Testing


WuXi’s medical device testing experts provide end-to-end regulatory and technical support to bring your medical devices to market.

End-to-End Services

Analytical Services


The Analytical Services Unit provides both early and late-phase analytical support, including integrated CMC services from IND to NDA and beyond.

Bioanalytical Services


Bioanalytical Services at the Laboratory Testing Division support in vitro ADME, discovery biology, PK, PD and discovery toxicology from NCE through IND.

DMPK Services


The Laboratory Testing Division provides comprehensive in vitro and in vivo ADMET solutions from high-throughput screening in discovery through drug development phases.

Toxicology Services


Our skilled team of toxicologists provide comprehensive safety assessments across a wide range of species and through various routes of administration.

Highlights

Learn how our DMPK discovery package can accelerate your drug development timeline

View our list of validated bioanalytical methods

See our leadership team discuss the benefits of WIND at AAPS

View WuXipress